Evaluation of 3-, 6- and 9-day post-treatment intervals following pradofloxacin for treatment of bovine respiratory disease in stocker cattle
American Association of Bovine Practitioners Conference Proceedings · 28.04.2026 · 58 (2) · 231
DOI: 10.21423/aabppro20259415 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Association of Bovine Practitioners Conference Proceedings, online erschienen am 28.04.2026. Verfasst von L. Heinen und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Pradofloxacin is a fluroquinolone antimicrobial approved for bovine respiratory disease (BRD) treatment in cattle in the United States. Establishment of an appropriate post-treatment interval (PTI) following antimicrobial treatment for BRD should be made based on clinical outcomes. The study objective was to compare different PTIs following therapy with pradofloxacin on first treatment success, case fatality and days to death in stocker cattle with naturally occurring BRD.
Zitieren
APA
Heinen, L., Lubbers, B., Tessman, R., Amachawadi, R., & White, B. (2026). Evaluation of 3-, 6- and 9-day post-treatment intervals following pradofloxacin for treatment of bovine respiratory disease in stocker cattle. American Association of Bovine Practitioners Conference Proceedings, 58(2), 231. https://doi.org/10.21423/aabppro20259415
Vancouver
Heinen L, Lubbers B, Tessman R, Amachawadi R, White B. Evaluation of 3-, 6- and 9-day post-treatment intervals following pradofloxacin for treatment of bovine respiratory disease in stocker cattle. American Association of Bovine Practitioners Conference Proceedings. 2026;58(2):231. doi:10.21423/aabppro20259415
BibTeX
@article{Heinen2026,
author = {Heinen, L. and Lubbers, B. and Tessman, R. and Amachawadi, R.G. and White, B.},
title = {Evaluation of 3-, 6- and 9-day post-treatment intervals following pradofloxacin for treatment of bovine respiratory disease in stocker cattle},
journal = {American Association of Bovine Practitioners Conference Proceedings},
year = {2026},
volume = {58},
number = {2},
pages = {231},
doi = {10.21423/aabppro20259415}
}
EUVIMED